HOME > TOP STORIES
TOP STORIES
-
REGULATORY Japan’s New PM Eyes Social Security Reform as Cabinet Unveiled
October 2, 2024
-
REGULATORY Takamaro Fukuoka Named as New Health Minister
October 1, 2024
-
REGULATORY Japan Compiles First Biosimilar Roadmap
October 1, 2024
-
ACADEMIA Pharmacies, Hospitals Scrambling to Address New LLP Coverage Rule, Concerns Swirl Around Misuse
October 1, 2024
-
REGULATORY Ishiba Elected as New LDP Leader, Hopes Are High for Medical and Pharma Policies
September 30, 2024
-
REGULATORY MHLW to Publish Info Necessary for Driving Biosimilar Switches in FY2025
September 27, 2024
-
REGULATORY Kisunla Subject to Prior Pricing Review as It Follows Leqembi’s Footsteps
September 26, 2024
-
REGULATORY Japan Approves Lilly’s Kisunla, Eisai’s ALS Med, Gilead’s Trodelvy, and Lots More
September 25, 2024
-
BUSINESS NHI-Market Price Gap on Narrowing Trend, but Results Remain Unpredictable
September 24, 2024
-
REGULATORY More Pregnant Cases Reported for COVID Meds, Panel Urges Greater Caution
September 24, 2024
-
BUSINESS Tsumura to Cover Return Costs for China Staff after Shenzhen Stabbing
September 24, 2024
-
REGULATORY MHLW to Update Decade-Old Generic Roadmap, Add Blueprint for Biosimilars
September 20, 2024
-
BUSINESS Asahi Kasei Pivots toward Drug Business in Healthcare to Drive Growth
September 19, 2024
-
BUSINESS UCB CEO Hails Positive Change in Japan’s Pharma Policy
September 19, 2024
-
BUSINESS GSK’s Multiple Myeloma Drug Blenrep Filed in Japan
September 18, 2024
-
REGULATORY 9 LDP Leader Candidates Showcase Pharma Agendas in Campaign
September 17, 2024
-
BUSINESS Eisai Set on Streamlining Operations to Drive Drug Innovation: COO
September 13, 2024
-
ORGANIZATION Pharma Industry Prepares List of 68 Lawmakers to Support in Likely Snap Poll
September 12, 2024
-
REGULATORY Mounjaro to Keep Price after CEA as Lilly’s Appeal for Raise Nixed
September 12, 2024
-
REGULATORY AMED Research Exploring Low-Cost Method to Analyze Nitrosamine Impurities
September 11, 2024
ページ
We had just gotten off a call with a client in Europe, and we’d received a bit of an earful. “Philip,” the client pressed, “what can this candidate bring to us? We know what he does, but what has he…
